Professional Documents
Culture Documents
M.F. Alves1, M.C. Araujo1, 1Departamento de Biofísica, 2Disciplina de Nefrologia, Departamento de Medicina,
M.A. Juliano1, E.M. Oliveira4, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil
J.E. Krieger3, D.E. Casarini2, 3Laboratório de Genética e Cardiologia Molecular, Instituto do Coração,
L. Juliano1 and A.K. Carmona1 Faculdade de Medicina, 4Laboratório de Bioquímica da Atividade Motora,
Escola de Educação Física e Esporte, Universidade de São Paulo, São Paulo, SP, Brasil
Abstract
Correspondence A continuous assay using internally quenched fluorescent peptides Key words
A.K. Carmona with the general sequence Abz-peptidyl-(Dnp)P-OH (Abz = ortho- • Angiotensin-converting
Departamento de Biofísica aminobenzoic acid; Dnp = 2,4-dinitrophenyl) was optimized for the enzyme activity
EPM, UNIFESP
measurement of angiotensin I-converting enzyme (ACE) in human • Fluorometric assay
Rua 3 de Maio, 100 • Rat tissue angiotensin-
04044-020 São Paulo, SP
plasma and rat tissues. Abz-FRK(Dnp)P-OH, which was cleaved at
converting enzyme
Brasil the Arg-Lys bond by ACE, was used for the enzyme evaluation in
• Human plasma
E-mail: adriana@biofis.epm.br human plasma. Enzymatic activity was monitored by continuous
angiotensin-converting
recording of the fluorescence (λex = 320 nm and λem = 420 nm) at 37oC, enzyme
Research supported by FAPESP in 0.1 M Tris-HCl buffer, pH 7.0, with 50 mM NaCl and 10 µM ZnCl2.
and CNPq. The assays can be performed directly in the cuvette of the fluorimeter
and the hydrolysis followed for 5 to 10 min. ACE measurements in the
plasma of 80 healthy patients with Hip-His-Leu and with Abz-
Received September 22, 2004
FRK(Dnp)P-OH correlated closely (r = 0.90, P < 0.001). The specific-
Accepted April 5, 2005 ity of the assay was demonstrated by the complete inhibition of
hydrolysis by 0.5 µM lisinopril or captopril. Abz-FRK(Dnp)P-OH
cleavage by ACE was monitored in rat lung, kidney, heart, and liver
homogenates in the presence of a cocktail of inhibitors containing
trans-epoxy-succinyl-L-leucylamido-(4-guanido)-butene, pepstatin,
phenyl-methylsulfonyl fluoride, N-tosyl-L-phenylalanyl-chloromethyl
ketone, and N-tosyl-lysyl-chloromethyl ketone to prevent undesirable
hydrolysis. ACE activity in lung, heart and kidney homogenates, but
not in liver homogenates, was completely abolished by 0.5 µM
lisinopril or captopril. The advantages of the method are the proce-
dural simplicity and the high sensitivity providing a rapid assay for
ACE determinations.
dipeptides (2). ACE is expressed as a so- acid and EDDnp is 2,4-dinitrophenyl ethyl-
matic isoform (150-180 kDa) in endothelial, enediamine) or free (Abz-peptidyl-K(Dnp)P-
epithelial and neuroepithelial cells and as a OH) C-terminal carboxyl groups (22,23). In
smaller isoform (90-110 kDa) only in germi- the present study, we describe the suscepti-
nal cells in the testes. Somatic ACE is an bility of Abz-peptidyl-K(Dnp)P-OH deriva-
ectoenzyme attached to the cell membrane tives to hydrolysis by ACE from purified
composed of two highly homologous do- rabbit lung. We also describe the use of these
mains, N- and C-domains, each possessing a substrates for ACE activity determinations
functional active site (3,4). The germinal in human plasma and in crude extracts of rat
form of ACE is also a membrane-bound tissues. These internally quenched fluoro-
enzyme which contains a single active site genic substrates provide a very sensitive
corresponding to the C-domain of the so- method for ACE determinations and can be
matic form (5,6). Plasma or soluble ACE is used on a continuous basis even at low ACE
derived from proteolytic shedding from the concentrations. In addition, since the fluo-
cell membrane (7,8). rescence signal appears immediately after
ACE is found in the plasma membrane of hydrolysis, subsequent digestion of the prod-
vascular endothelial cells, with high levels ucts of ACE activity will not interfere with
being present in the lung vascular endotheli- the enzyme activity measurement.
al surface but the enzyme can be also found
in the epithelial cells of renal proximal tu- Material and Methods
bules, in the gastrointestinal tract, in cardiac
tissues, and in various regions of the brain Material
(9,10). This wide distribution of the enzyme
and its presence in many tissues where other Captopril, lisinopril, trans-epoxy-succi-
components of the renin-angiotensin system nyl-L-leucylamido-(4-guanido)-butene (E-
are not present reinforce the idea that ACE 64), phenyl-methylsulfonyl fluoride (PMSF),
probably has other roles in addition to the pepstatin, N-tosyl-L-phenylalanyl-chloro-
production of angiotensin II or the inactiva- methyl ketone (TPCK), N-tosyl-lysyl-chlo-
tion of bradykinin (11,12). romethyl ketone (TLCK), and ortho-phthal-
The hydrolysis of synthetic substrates dialdehyde were from Sigma (St. Louis, MO,
used for assaying ACE activity is detected USA). All other chemicals were of reagent
by spectrophotometric (13,14), fluorometric grade.
(15-18), HPLC (19), radiometric (20), and
radioimmunoassay (21) methods. However, Peptide synthesis
each of these techniques has its own limita-
tions, such as being very laborious, having Hippuryl-His-Leu (Hip-His-Leu) and
low sensitivity, or employing substrates His-Leu were synthesized as described
whose products resulting from ACE activity (24,25). The internally quenched fluorogen-
are destroyed by other enzymes, with a con- ic peptides containing the Dnp group incor-
sequent underestimate of ACE levels. There- porated into the ε-NH2 of a Lys residue were
fore, convenient and specific substrates are synthesized by the solid-phase methodol-
still required for the determination of ACE ogy, using Fmoc technology and H-Pro-2-
activity in biological fluids and tissues. chlorotrityl resin (26). All the peptides ob-
We have described internally quenched tained were purified by semi-preparative
fluorogenic substrates for ACE with blocked HPLC, and the molecular weight and purity
(Abz-peptidyl-EDDnp analogues of brady- were checked by amino acid analysis and by
kinin where Abz is ortho-amino benzoic molecular mass determination with MALDI-
TOF mass spectrometry, using a TofSpec E pH 7.0 (1.0 ml final volume). Enzymatic
from Micromass (Manchester, UK). Stock activity was continuously monitored with a
solutions of the fluorogenic peptides were Hitachi F-2000 (Tokyo, Japan) fluorometer
prepared in DMSO and the concentrations by measuring fluorescence at λex = 320 nm
were determined using the EDDnp molar and λem = 420 nm. The slope was converted
extinction coefficient ε365 = 17,300 M-1 cm-1. into µmol substrate hydrolyzed/minute on
the basis of a calibration curve obtained after
Enzymes complete hydrolysis of each peptide. For the
determination of the kinetic parameters the
Purified rabbit lung ACE was purchased enzyme concentration was chosen so as to
from Sigma. The molar concentration of the hydrolyze less than 5% of the substrate pres-
enzyme was determined by active site titra- ent per unit time in order to obtain the initial
tion with lisinopril as described (27). rate. To correct for the inner filter effect we
used an adjusting equation determined ex-
Human plasma samples perimentally for 0.1 to 100 µM Abz-FR-OH,
used as standard for fluorescence measure-
Blood was obtained from healthy donors ments (23). The kcat/Km values were calcu-
by arm venipuncture. All subjects gave writ- lated from the kinetic parameters kcat and Km
ten informed consent to participate in the obtained by analysis of the non-linear re-
study. The protocol was approved by the gression data with the GraFit program (29).
Ethics Committee on Human Experimenta- The standard deviations of the kcat and Km
tion (Hospital São Paulo, Universidade Fe- values were less than 7%.
deral de São Paulo, São Paulo, SP, Brazil).
For the study, heparin-treated blood was Determination of substrate cleavage site
centrifuged at 1000 g for 10 min and plasma
was removed and stored at -20ºC. The scissile bonds of the hydrolyzed pep-
tides were determined by isolation of the
Crude aqueous extracts of rat tissues fragments by analytical HPLC, and their
structures deduced by amino acid sequenc-
Samples of Wistar rat (200-250 g) lung, ing using a PPSQ-23 protein sequencer (Shi-
kidney, heart, and liver were quickly har- madzu, Tokyo, Japan) and by MALDI-TOF
vested, rinsed, blotted, and homogenized in mass spectrometry.
Tris-HCl buffer, pH 7.0, containing 50 mM
NaCl. Homogenates were centrifuged at 1000 Determination of ACE activity in human
g for 10 min and the supernatant was frozen plasma
at -20ºC. The protein contents of the samples
were measured by the method of Bradford Measurement of human plasma ACE ac-
(28) using bovine serum albumin as stand- tivity using Hip-His-Leu as substrate was
ard. performed by the fluorometric method de-
scribed by Friedland and Silverstein (15).
Determination of kinetic parameters for Briefly, 10 µl serum was added to the assay
Abz-peptidyl-K(Dnp)P-OH derivatives solution containing 5 mM Hip-His-Leu in
0.1 M potassium phosphate buffer, pH 8.3,
The purified rabbit lung ACE activity on containing 0.3 M NaCl, at 37ºC, in a final
Abz-FRK(Dnp)P-OH derivatives was deter- volume of 250 µl. The product, His-Leu, was
mined at 37ºC in 0.1 M Tris-HCl buffer quantified by measuring the fluorescent ad-
containing 50 mM NaCl and 10 µM ZnCl2, duct formed with ortho-phthaldialdehyde
Abz-FRK(Dnp)P-OH was used as sub- Experimental conditions: the assays were performed at 37ºC in 0.1 M Tris-HCl, pH 7.0,
containing 50 mM NaCl and 10 µM ZnCl2, in a final volume of 1.0 ml.
strate to quantify ACE activity in human *A relative kcat/Km value of 1.0 was assigned to Abz-FRK(Dnp)P-OH which was
plasma. Fluorescence appeared after cleav- hydrolyzed with the highest catalytic efficiency. Abz-FRK(Dnp)P-OH = ortho-ami-
nobenzoic acid-FRK-(2,4-dinitrophenyl)P-OH.
age of the Arg-Lys(Dnp) bond as shown by
HPLC analysis and amino acid sequencing
of the reaction products. The assay required Figure 1. Linear relation-
as little as 1 µl plasma in a final volume of ship between the ve-
locity of hydrolysis of 10
1 ml. A linear relationship between the rate µM Abz-FRK(Dnp)P-OH
of hydrolysis and the volume of human and the volume of hu-
plasma added was observed in the range man plasma. In the in-
set, continuous fluores-
investigated, 1 to 10 µl (Figure 1). Regres-
cence recording of the
sion analysis was performed on data for 80 substrate hydrolysis by
healthy patients using Hip-His-Leu and Abz- plasma: 1 µl (circles), 2
FRK(Dnp)P-OH as substrates, as shown in µl (squares), 5 µl (filled
triangles), 10 µl (filled in-
Figure 2. The paired Student t-test indicated verted triangles), and 10
that the results obtained correlated and were µl + 0.5 µM lisinopril (loz-
significant (r = 0.90, P < 0.001). The hy- enges). The slope was
converted into µmol of
drolysis of Abz-FRK(Dnp)P-OH by human substrate hydrolyzed/
plasma was completely inhibited by 0.5 µM min based on a calibra-
lisinopril or captopril, demonstrating the tion curve obtained from
complete hydrolysis of Abz-FRK(Dnp)P-OH (slope = 4600 AFU/µM of Abz-FR). Abz-
specificity of the assay. FRK(Dnp)P-OH = ortho-aminobenzoic acid-FRK-(2,4-dinitrophenyl)P-OH. Measurements
were made in duplicate and differences were <5%.
ACE activity in rat tissues
Figure 2. Linear regres-
sion analysis of paired
ACE activities in tissue homogenates of data of angiotensin I-con-
rat lung, kidney, heart, and liver were exam- verting enzyme activity in
ined using Abz-FRK(Dnp)P-OH as substrate. plasma from 80 normal
patients using Hip-His-
In these assays, classical inhibitors of cys- Leu (x-axis) and Abz-
teine, aspartyl and serine peptidases (10 µM FRK(Dnp)P-OH (y-axis)
E64, 1 µM pepstatin, 1 mM PMSF, 100 µM as substrates. In the
Friedland and Silverstein
TLCK, and 100 µM TPCK) were added to method (15), ACE activ-
prevent undesirable hydrolysis. Except for ity was measured in 10 µl
the liver extracts, in which the hydrolysis of plasma with 5 mM Hip-
Abz-FRK(Dnp)P-OH was only partially His-Leu as substrate, in
a final volume of 250 µl.
blocked (58%), in lung, heart and kidney the In the method described
cleavage of this substrate was completely here, 5 µl plasma was in-
abolished by 0.5 µM lisinopril or captopril cubated with 10 µM Abz-
FRK(Dnp)P-OH in a final volume of 1.0 ml. Abz-FRK(Dnp)P-OH = ortho-aminobenzoic
(Table 2). The residual activity in the liver acid-FRK-(2,4-dinitrophenyl)P-OH. The correlation coefficient was r = 0.90, P < 0.001;
was inhibited by the addition of 1 mM ortho- paired Student t-test). The assays were performed in duplicate and differences were <10%.
phenanthroline, indicating the interference in the liver and the hydrolysis of Abz-
of a metallopeptidase other than ACE (data FRK(Dnp)P-OH by an enzyme different from
not shown). ACE, this substrate is not convenient for
The sensitivity of the assay can be evalu- ACE determinations in crude extracts of
ated from the data presented in Table 2. As liver.
expected, ACE activity was much higher in Figure 3 shows the sensitivity of Abz-
the lung compared to the other tissues. How- FRK(Dnp)P-OH for ACE activity detection
ever, due to the small amount of the enzyme at different protein concentrations of rat lung
and kidney. Using this substrate, reliable
Table 2. Rat tissue ACE activity measurements with Abz-FRK(Dnp)P-OH and inhibi-
ACE activity measurements can be made
tion with 0.5 µM lisinopril or captopril. with as little as 0.3 µg lung homogenate
while 10 µg kidney homogenate is needed
Substrate mU per mg of protein (inhibition, %)
for the enzyme measurement.
Lung Kidney Heart Liver
Discussion
Abz-FRK(Dnp)P-OH 71.2 (100) 1.1 (100) 0.4 (100) 0.1 (58)
Experimental conditions: the assays were performed at 37ºC in 0.1 M Tris-HCl, pH 7.0, ACE measurement in human plasma and
containing 50 mM NaCl, 10 µM ZnCl2, 10 µM E64, 1 µM pepstatin, 1 mmol/l PMSF, 100 tissues can provide essential information for
µM TLCK, and 100 µmol/l TPCK, in a final volume of 1.0 ml. Substrate: 10 µM. ACE = the investigation of some physiological and
angiotensin converting enzyme; Abz-FRK(Dnp)P-OH = ortho-aminobenzoic acid-FRK-
(2,4-dinitrophenyl)P-OH; PMSF = phenyl-methylsulfonyl fluoride; TPCK = N-tosyl-L-
pathophysiological situations. Colorimetric,
phenylalanyl-chloromethyl ketone; TLCK = N-tosyl-lysyl-chloromethyl ketone. fluorometric and radiolabeled assays have
been described to monitor the enzyme activ-
Figure 3. Effect of protein
ity. However, all of these methods have
concentration on the hydro- some limitations. We have previously de-
lytic activity of rat tissue ho- scribed internally quenched fluorogenic
mogenates on 10 µM Abz-
FRK(Dnp)P-OH. Initial rates
bradykinin-related peptides bearing a
of hydrolysis were deter- blocked C-terminal carboxyl group (Abz-
mined as shown in the in- peptidyl-EDDnp) for ACE determination in
sets. A, Lung homogenate
purified enzyme preparations and in human
under different concentra-
tions; inset : continuously plasma (22). Later, we reported the develop-
fluorescence recording of ment of highly efficient fluorogenic sub-
the hydrolysis by 0.8 µg strates for the enzyme with the general se-
protein in absence (circles),
in presence of the cocktail quence Abz-peptidyl-K(Dnp)P-OH (23). The
of inhibitors (squares) and activity of recombinant ACEs upon these
in presence of the cocktail peptides with a free C-terminal carboxyl
of inhibitors plus 0.5 µM lisi-
nopril (triangles). B, Kidney
group was significantly more efficient than
homogenate; inset : initial the activity described for Abz-peptidyl-
hydrolysis rate determina- EDDnp analogues of bradykinin. The ki-
tion: 30 µg protein in ab-
sence (circles) and in pres-
netic parameters for hydrolysis of Abz-
ence of the cocktail of in- FRK(Dnp)P-OH and Abz-YRK(Dnp)P-OH
hibitors (squares) and with by wild-type human recombinant ACE clas-
0.5 µM lisinopril (triangles).
sify these peptides among the best substrates
Abz-FRK(Dnp)P-OH = ortho-
aminobenzoic acid-FRK- described for ACE (23). The improvement
(2,4-dinitrophenyl)P-OH. in the sensitivity of the assay and the great
Measurements were made
interest in the development of a method for
in duplicate and differences
were <5%. ACE determinations on a continuous basis
led us to standardize the assay for enzyme
References
1. Skeggs LT, Kahn JR & Shumway NP (1956). Preparation and Mouse angiotensin converting enzyme is a protein composed of two
function of the hypertensin converting enzyme. Journal of Experi- homologous domains. Journal of Biological Chemistry, 264: 11945-
mental Medicine, 103: 295-299. 11951.
2. Yang HYT, Erdös EG & Levin Y (1970). A dipeptidyl carboxypepti- 5. Lattion AL, Soubrier F, Allegrini J, Hubert C, Corvol P & Alhenc-
dase that converts angiotensin I and inactivates bradykinin. Bio- Gelas F (1989). The testicular transcript of angiotensin I-converting
chimica et Biophisica Acta, 214: 374-376. enzyme encodes for the ancestral, non-duplicated form of the en-
3. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear zyme. FEBS Letters, 252: 99-104.
G & Corvol P (1988). Two putative active centers in human angio- 6. Ehlers MRW, Fox EA, Strydom DJ & Riordan JF (1989). Molecular
tensin I-converting enzyme. Proceedings of the National Academy cloning of human testicular angiotensin-converting enzyme: the tes-
of Sciences, USA, 85: 9386-9390. tis isoenzyme is identical to the C-terminal half of endothelial angio-
4. Bernstein KE, Martin BM, Edwards AS & Bernstein EA (1989). tensin-converting enzyme. Proceedings of the National Academy of
Sciences, USA, 86: 7741-7745. 21. Alhenc-Gelais F, Weare JA, Johnson RL & Erdös EG (1983). Meas-
7. Wei L, Alhenc-Gelas F, Soubrier F, Michaud A, Corvol P & Clauser urement of human converting enzyme level by direct radioimmu-
E (1991). Expression and characterization of recombinant human noassay. Journal of Laboratory and Clinical Medicine, 101: 83-95.
angiotensin I-converting enzyme. Evidence for a C-terminal trans- 22. Araujo MC, Melo RL, Del Nery E, Alves MFM, Juliano MA, Casarini
membrane anchor and for a proteolytic processing of the secreted DE, Juliano L & Carmona AK (1999). Internally quenched fluorogen-
recombinant and plasma enzymes. Journal of Biological Chemistry, ic substrates for angiotensin I-converting enzyme. Journal of Hyper-
266: 5540-5546. tension, 17: 665-672.
8. Beldent V, Michaud A, Wei L, Chauvet MT & Corvol P (1993). 23. Araujo MC, Melo RL, Cesari MH, Juliano MA, Juliano L & Carmona
Proteolytic release of human angiotensin-converting enzyme. Jour- AK (2000). Peptidase specificity characterization of C- and N-termi-
nal of Biological Chemistry, 268: 26428-26434. nal catalytic sites of angiotensin I-converting enzyme. Biochemistry,
9. Cushman DW & Cheung HS (1971). Concentration of angiotensin- 39: 8519-8525.
converting enzyme in tissues of rat. Biochimica et Biophisica Acta, 24. Juliano MA & Juliano L (1985). Synthesis and kinetic parameters of
250: 261-265. hydrolysis by trypsin of some acyl-arginyl-p-nitroanilides and pep-
10. Mendelsohn FAO, Allen AM, Chai SY, McKinley MJ, Oldfield BJ & tides containing arginyl-p-nitroanilide. Brazilian Journal of Medical
Paxinos G (1990). The brain angiotensin system: insights from and Biological Research, 18: 435-445.
mapping its components. Trends in Endocrinology and Metabolism, 25. Hirata IY, Boschcov P, Oliveira MCF, Juliano MA, Miranda A,
1: 189-197. Chagas JR, Tsuboi S, Okada Y & Juliano L (1991). Synthesis of
11. Dzau VJ (1987). Implications of local angiotensin production in human angiotensinogen (1-17) containing one of the putative glyco-
cardiovascular physiology and pharmacology. American Journal of sylation binding sites and its hydrolysis by human renin and porcine
Cardiology, 59: 59-65. pepsin. International Journal of Peptide and Protein Research, 38:
12. Dzau VJ (1988). Circulating versus local renin angiotensin system I 298-307.
cardiovascular homeostasis. Circulation, 77: 4-13. 26. Barlos K, Gatos D, Rapolos S, Papaphotiu G, Schafer W & Yao WQ
13. Cushman DW & Cheung HS (1971). Spectrophotometric assay and (1989). Esterification of partially protected peptide-fragments with
properties of the angiotensin-converting enzyme of rabbit lung. Bio- resins - utilization of 2-chlorotritylchloride for synthesis of Leu-15-
chemical Pharmacology, 20: 1637-1648. gastrin-I. Tetrahedron Letters, 30: 3947-3950.
14. Holmquist B, Bunning P & Riordan JF (1979). A continuous spectro- 27. Ehlers MRW & Riordan JF (1991). Angiotensin-converting enzyme:
photometric assay for angiotensin converting enzyme. Analytical Zinc and inhibitor binding stoichiometries of the aromatic and testis
Biochemistry, 95: 540-548. enzymes. Biochemistry, 30: 7118-7126.
15. Friedland J & Silverstein E (1976). A sensitive fluorometric assay for 28. Bradford MM (1976). A rapid and sensitive method for the quantifi-
serum angiotensin converting enzyme. American Journal of Clinical cation of microgram quantities of protein utilizing the principle of
Pathology, 66: 416-424. protein-dye binding. Analytical Biochemistry, 72: 248-254.
16. Friedland J & Silverstein E (1977). Sensitive fluorometric assay for 29. Leatherbarrow RJ (1992). Grafit Version 3.0. Erithacus Software
serum angiotensin converting enzyme with natural substrate angio- Ltd., Staines, UK.
tensin I. American Journal of Clinical Pathology, 68: 225-228. 30. Colton T (1974). Statistics in Medicine. Little, Brown & Co., Boston,
17. Carmel A & Yaron A (1978). An intramolecularly quenched fluores- MA, USA.
cent tripeptide as a fluorogenic substrate of angiotensin I-converting 31. Cheung HS & Cushman DW (1973). Inhibition of homogeneous
enzyme and a bacterial dipeptidyl carboxypeptidase. European Jour- angiotensin-converting enzyme of rabbit lung by synthetic venom
nal of Biochemistry, 87: 265-273. peptides of Bothrops jararaca. Biochimica et Biophisica Acta, 293:
18. Oliveira EM, Santos RAS & Krieger JE (2000). Standardization of a 451-463.
fluorometric assay for the determination of tissue angiotensin-con- 32. Carvalho K, Nava RA, França MSF, Medeiros MAS, Camarão GC &
verting enzyme activity in rats. Brazilian Journal of Medical and Juliano L (1999). A liver metallopeptidase which degrades the circu-
Biological Research, 33: 755-764. lating hypotensive peptide hormone bradykinin and atrial natriuretic
19. Meng QC, Balcells E, Dell’Italia L, Durand J & Oparil S (1995). peptide. Brazilian Journal of Medical and Biological Research, 32:
Sensitive method for quantitation of angiotensin-converting enzyme 51-54.
(ACE) activity in tissue. Biochemical Pharmacology, 50: 1490-1498. 33. Molina HM, Carmona AK, Kouyoumdjian M & Borges DR (2000).
20. Rohrabach MS (1978). (Glycine-1 14C) Hippuryl-L-histidyl-L-leucine Thimet oligopeptidase EC 3.4.24.15 is a major liver kininase. Life
A substrate for the radiochemical assay of angiotensin converting Sciences, 67: 509-520.
enzyme. Analytical Biochemistry, 84: 272-276.